Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis

Journal of the Neurological Sciences

Volumn 319, Issue 1-2, 2012, Pages 2-7

  Mayer, Marie Cathrin ^a,b   Hohlfeld, Reinhard ^a,b   Meinl, Edgar ^a,b  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute disseminated encephalomyelitis; Autoantibody detection methods; Autoantigens; Biomarkers; Multiple sclerosis; Myelin oligodendrocyte glycoprotein

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BETA INTERFERON; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

B LYMPHOCYTE; BLOOD; CELL THERAPY; CEREBROSPINAL FLUID; CLINICAL PRACTICE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC HETEROGENEITY; HUMAN; MULTIPLE SCLEROSIS; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; TREATMENT PLANNING;

AUTOANTIBODIES; HUMANS; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 84862762578     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.05.018     Document Type: Review

References (55)

1. Davis JC, Furstenthal L, Desai AA, Norris T, Sutaria S, Fleming E, et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov Apr 2009;8(4):279-86.
2. Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med Mar 2001;7(3):115-21. (Pubitemid 32201673)
3. Hohlfeld R. 'Gimme five': future challenges in multiple sclerosis. ECTRIMS Lecture 2009. Mult Scler Jan 2010;16(1):3-14.
4. Brunner C, Lassmann H, Waehneldt TV, Matthieu JM, Linington C. Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats. J Neurochem Jan 1989;52(1):296-304. (Pubitemid 19023382)
5. Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein. Proc Natl Acad Sci U S A Aug 5 2003;100(16):9446-51. (Pubitemid 37033948)
6. Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG, et al. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci U S A Sep 16 2003;100(19):11059-64. (Pubitemid 37140152)
7. Breithaupt C, Schafer B, Pellkofer H, Huber R, Linington C, Jacob U. Demyelinating myelin oligodendrocyte glycoprotein-specific autoantibody response is focused on one dominant conformational epitope region in rodents. J Immunol Jul 15 2008;181(2):1255-63.
8. Johns TG, Bernard CC. Binding of complement component Clq to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol Immunol Jan 1997;34(1):33-8. (Pubitemid 27244533)
9. Cong H, Jiang Y, Tien P. Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus. J Virol Nov 2011;85(21):11038-47.
10. Delarasse C, Daubas P, Mars LT, Vizler C, Litzenburger T, Iglesias A, et al. Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. J Clin Invest Aug 2003;112(4):544-53. (Pubitemid 38056339)
11. Xiao BG, Linington C, Link H. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol Feb 1991;31(2):91-6.
12. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain Nov 1999;122(Pt. 11):2047-56.
13. Gaertner S, de Graaf KL, Greve B, Weissert R. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology Dec 28 2004;63(12):2381-3. (Pubitemid 40024355)
14. Wang H, Munger KL, Reindl M, O'Reilly EJ, Levin LI, Berger T, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology Oct 7 2008;71(15):1142-6.
15. Klawiter EC, Piccio L, Lyons JA, Mikesell R, O'Connor KC, Cross AH. Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Arch Neurol Sep 2010;67(9):1102-8.
16. Haase CG, Guggenmos J, Brehm U, Andersson M, Olsson T, Reindl M, et al. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol Mar 1 2001;114(1-2):220-5. (Pubitemid 32184745)
17. Gori F, Mulinacci B, Massai L, Avolio C, Caragnano M, Peroni E, et al. IgG and IgM antibodies to the refolded MOG(1-125) extracellular domain in humans. J Neuroimmunol Apr 2011;233(1-2):216-20.
18. Menge T, von Budingen HC, Lalive PH, Genain CP. Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solidphase ELISA. Eur J Immunol Nov 2007;37(11):3229-39. (Pubitemid 350131301)
19. O'Connor KC, Appel H, Bregoli L, Call ME, Catz I, Chan JA, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol Aug 1 2005;175(3):1974-82. (Pubitemid 41023105)
20. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med Feb 1999;5(2):170-5. (Pubitemid 29068523)
21. Lindert RB, Haase CG, Brehm U, Linington C, Wekerle H, Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain Nov 1999;122(Pt. 11):2089-100.
22. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med Jul 10 2003;349(2):139-45. (Pubitemid 36818783)
23. Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med Jan 25 2007;356(4):371-8. (Pubitemid 46148779)
24. Pelayo R, Tintore M, Montalban X, Rovira A, Espejo C, Reindl M, et al. Antimyelin antibodies with no progression to multiple sclerosis. N Engl J Med Jan 25 2007;356(4):426-8. (Pubitemid 46148809)
25. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, BruckW, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A Dec 12 2006;103(50):19057-62. (Pubitemid 350002827)
26. O'Connor KC,McLaughlin KA, De Jager PL, Chitnis T, Bettelli E, Xu C, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med Feb 2007;13(2):211-7.
27. Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol Dec 2009;66(6): 833-42.
28. Di Pauli F, Mader S, Rostasy K, Schanda K, Bajer-Kornek B, Ehling R, et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol Mar 2011;138(3):247-54.
29. Lalive PH, Menge T, Delarasse C, Della GB, Pham-Dinh D, Villoslada P, et al. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci U S A Feb 14 2006;103(7):2280-5. (Pubitemid 43271661)
30. Lalive PH, Hausler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler Mar 2011;17(3):297-302.
31. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Agedependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol Sep 15 2009;183(6):4067-76.
32. Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology Aug 9 2011;77(6):580-8.
33. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology Oct 22 2002;59(8): 1224-31. (Pubitemid 35192393)
34. Selter RC, Brilot F, Grummel V, Kraus V, Cepok S, Dale RC, et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology May 25 2010;74(21):1711-5.
35. Rostasy K, Mader S, Schanda K, Huppke P, Gartner J, Kraus V, et al. Anti-MOG antibodies in children with optic neuritis. Arch Neurol [2012 Feb 27 Electronic publication ahead of print].
36. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011;8:184.
37. Menge T, Kieseier BC, Nessler S, Hemmer B, Hartung HP, Stuve O. Acute disseminated encephalomyelitis: an acute hit against the brain. Curr Opin Neurol Jun 2007;20(3):247-54. (Pubitemid 46743104)
38. Kieseier BC, Stuve O. A critical appraisal of treatment decisions inmultiple sclerosis - old versus new. Nat Rev Neurol May 2011;7(5):255-62.
39. Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Longterm follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology Apr 12 2011;76(15):1310-5.
40. Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol Aug 2010;67(8):1016-7.
41. Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, Kumpfel T, Pellkofer H, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain Jun 2008;131(Pt. 6):1455-63. (Pubitemid 351806460)
42. Brehm U, Piddlesden SJ, Gardinier MV, Linington C. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J Neuroimmunol Jun 1 1999;97(1-2):9-15. (Pubitemid 29301408)
43. Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol Aug 1993;143(2):555-64. (Pubitemid 24058211)
44. Litzenburger T, Fassler R, Bauer J, Lassmann H, Linington C, Wekerle H, et al. B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J Exp Med Jul 6 1998;188(1):169-80. (Pubitemid 28328615)
45. Poser CM, Brinar VV. Disseminated encephalomyelitis and multiple sclerosis: two different diseases - a critical review. Acta Neurol Scand Oct 2007;116(4):201-6. (Pubitemid 47373490)
46. Waubant E, Chabas D,Okuda DT, Glenn O,Mowry E,Henry RG, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol Aug 2009;66(8):967-71.
47. Keegan M, Konig F, McClelland R, Bruck W, Morales Y, Bitsch A, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet Aug 13 2005;366(9485):579-82. (Pubitemid 41140333)
48. Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, Krumbholz M, et al. Contactin- 2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A May 19 2009;106(20):8302-7.
49. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med Oct 1 2007;204(10):2363-72. (Pubitemid 47529322)
50. Derfuss T, Linington C, Hohlfeld R, Meinl E. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med Aug 2010;88(8):753-61.
51. Lovato L, Cianti R, Gini B, Marconi S, Bianchi L, Armini A, et al. Transketolase and 2′,3′-cyclic-nucleotide 3′-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients. Mol Cell Proteomics Dec 2008;7(12):2337-49.
52. Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A Dec 2 2008;105(48):18889-94.
53. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med Jan 2006;12(1):138-43. (Pubitemid 43050089)
54. Della Gaspera B, Pham-Dinh D, Roussel G, Nussbaum JL, Dautigny A. Membrane topology of the myelin/oligodendrocyte glycoprotein. Eur J Biochem Dec 1 1998;258(2):478-84. (Pubitemid 28557913)
55. Pham-Dinh D, Mattei MG, Nussbaum JL, Roussel G, Pontarotti P, Roeckel N, et al. Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex. Proc Natl Acad Sci U S A Sep 1 1993;90(17):7990-4. (Pubitemid 23260840)